Reduction of Post-operative Endodontic Pain

NCT ID: NCT01480752

Last Updated: 2013-01-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine the effect of intraligamentary injection of Lornoxicam on the intensity of post-operative endodontic pain in the tooth with symptomatic irreversible pulpitis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

sixty qualified samples (initial estimate which will be come more accurate after the pilot study on 6 patients) will be divided randomly in three groups which all of them will have an inferior Alveolar injection and before the beginning of the treatment the primary group will receive an injection of 0.4 mL ( 0.2 mL in mesio buccal and 0.2 mL in disto buccal) of Lornoxicam and the second group will be injected with 0.4 mL of normal saline( 0.2 mL in mesio buccal and 0.2 mL in disto buccal) ,in third group we will only pretend the injection but actually there is no substance injected ,making the patient believe that there was an injection . Then the patients' pain will be evaluated with visual Analogue Scale analysis (VAS) 0-170 mm in time intervals of 6, 12, 24 and 48 hours after the treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post Operative Endodontic Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lornoxicam

Group Type ACTIVE_COMPARATOR

Lornoxicam

Intervention Type DRUG

PDL injection of 0/2 ml of lornoxicam (4mg/ml),before the root therapy and after the inferior alveolar injection

normal saline

Group Type PLACEBO_COMPARATOR

normal saline

Intervention Type DRUG

PDl injection of 0/2 ml normal saline before the root therapy and after inferior alveolar injection

no injection

Group Type PLACEBO_COMPARATOR

no injection

Intervention Type DRUG

inject nothing after inferior alveolar injection and before root canal therapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lornoxicam

PDL injection of 0/2 ml of lornoxicam (4mg/ml),before the root therapy and after the inferior alveolar injection

Intervention Type DRUG

normal saline

PDl injection of 0/2 ml normal saline before the root therapy and after inferior alveolar injection

Intervention Type DRUG

no injection

inject nothing after inferior alveolar injection and before root canal therapy

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Xefo (904111)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy (ASA I, II);
* Patients with first or second mandibular molars who need endodontic treatment;
* Vital tooth without a history of past endodontic treatment;
* Patients with clinical evidence of irreversible Pulpits with moderate to severe pain;
* Patients without pre apical lesion and periodontal ligament enlargement more than 0.75-1mm on the x-ray images;
* Patients in the age group of 18-65 years old

Exclusion Criteria

* Pregnant or nursing;
* necrotic tooth;
* Patients with allergy or contraindication toward non-opioid or opioid painkillers such as aspirin or NSAIDs;
* People who have a history of acute peptic ulcer, during the past 12 months;
* People who have bleeding problems or have been taking anticoagulant drugs over the past month;
* Patients who have taken opioid or non opioid or steroid pain killers, antidepressants or sedative drugs.
Minimum Eligible Age

16 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Islamic Azad University, Sanandaj

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mandana Abedi Tari

principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dental School of Azad University

Tehran, Tehran Province, Iran

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Iran

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRCT201108017191N1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of Oral Analgesics on Post-op Pain
NCT07204379 COMPLETED EARLY_PHASE1
Pre-Emptive Analgesia in Dental Implant Surgery
NCT03243032 WITHDRAWN EARLY_PHASE1
Pain Control Following Third Molar Surgery
NCT06514222 ACTIVE_NOT_RECRUITING EARLY_PHASE1
Hyaluronidase Enzymes and Local Anesthesia
NCT06980363 NOT_YET_RECRUITING PHASE1